Neurotech International Ltd (ASX: NTI) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neurotech International Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$72.42 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.03 billion
Earnings per share
-0.006
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neurotech International Ltd (ASX: NTI)
Latest News
No posts found.
NTI ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neurotech International Ltd
Neurotech International Ltd is a medical device and solutions company conducting clinical studies to assess the neuroprotective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. Geographically, all the firm's business activities function through the region of Australia. It operates in one segment: Medical Device Development and Distribution.
NTI Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 28 Nov 2024 | $0.07 | $0.00 | 0.00% | 237,091 | $0.07 | $0.07 | $0.07 |
| 27 Nov 2024 | $0.07 | $0.00 | 0.00% | 2,097,631 | $0.07 | $0.07 | $0.07 |
| 26 Nov 2024 | $0.07 | $0.00 | 0.00% | 4,481,052 | $0.07 | $0.07 | $0.07 |
| 25 Nov 2024 | $0.07 | $0.00 | 0.00% | 1,107,794 | $0.07 | $0.07 | $0.07 |
| 22 Nov 2024 | $0.07 | $0.00 | 0.00% | 648,215 | $0.07 | $0.07 | $0.07 |
| 21 Nov 2024 | $0.07 | $0.00 | 0.00% | 569,246 | $0.07 | $0.07 | $0.07 |
| 20 Nov 2024 | $0.07 | $0.01 | 16.39% | 1,218,089 | $0.06 | $0.07 | $0.06 |
| 19 Nov 2024 | $0.06 | $0.00 | 0.00% | 747,778 | $0.06 | $0.06 | $0.06 |
| 18 Nov 2024 | $0.06 | $0.00 | 0.00% | 153,645 | $0.06 | $0.06 | $0.06 |
| 15 Nov 2024 | $0.06 | $0.00 | 0.00% | 1,042,951 | $0.06 | $0.06 | $0.06 |
| 14 Nov 2024 | $0.06 | $0.00 | 0.00% | 488,816 | $0.05 | $0.06 | $0.05 |
| 13 Nov 2024 | $0.05 | $0.00 | 0.00% | 814,411 | $0.06 | $0.06 | $0.05 |
| 12 Nov 2024 | $0.06 | $0.00 | 0.00% | 184,482 | $0.05 | $0.06 | $0.05 |
| 11 Nov 2024 | $0.05 | $0.00 | 0.00% | 886,498 | $0.05 | $0.06 | $0.05 |
| 08 Nov 2024 | $0.05 | $0.00 | 0.00% | 629,518 | $0.05 | $0.06 | $0.05 |
| 07 Nov 2024 | $0.05 | $0.00 | 0.00% | 124,233 | $0.05 | $0.06 | $0.05 |
| 06 Nov 2024 | $0.05 | $0.00 | 0.00% | 164,200 | $0.05 | $0.05 | $0.05 |
| 05 Nov 2024 | $0.05 | $0.00 | 0.00% | 573,764 | $0.05 | $0.06 | $0.05 |
| 04 Nov 2024 | $0.06 | $0.00 | 0.00% | 489,975 | $0.06 | $0.06 | $0.05 |
| 01 Nov 2024 | $0.06 | $0.00 | 0.00% | 12,362 | $0.06 | $0.06 | $0.06 |
| 31 Oct 2024 | $0.06 | $0.01 | 19.23% | 390,028 | $0.05 | $0.06 | $0.05 |
| 30 Oct 2024 | $0.05 | $0.00 | 0.00% | 497,178 | $0.05 | $0.05 | $0.05 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Sep 2024 | Robert (Max) Johnston | Issued | 1,000,000 | $60,000 |
Issue of options.
|
| 07 May 2024 | Robert (Max) Johnston | Buy | 500,000 | $45,000 |
Off-market trade.
|
| 29 Jan 2024 | Thomas (Tom) Duthy | Buy | 340,000 | $30,820 |
On-market trade.
|
| 30 Nov 2023 | Mark Davies | Buy | 2,000,000 | $76,000 |
Exercise of options. As per announcement on 01/12/2023
|
| 30 Nov 2023 | Mark Davies | Exercise | 2,000,000 | $76,000 |
Exercise of options. As per announcement on 01/12/2023
|
| 30 Nov 2023 | Winton Willesee | Exercise | 2,000,000 | $114,000 |
Exercise of options. As per announcement on 01/12/2023
|
| 30 Nov 2023 | Winton Willesee | Buy | 2,000,000 | $114,000 |
Exercise of options. As per announcement on 01/12/2023
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Apr 2024 |
Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the healthcare company for 11 years. Prior to this appointment, his career included several positions within Johnson and Johnson, both within Australia and overseas encompassing Europe and Asia. Mr Johnston's career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several prominent industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASMI.
|
| Dr Thomas (Tom) Duthy | Executive Director | Sep 2022 |
Dr Duthy has over 19 years of direct financial market and executive level/Board experience with ASX-listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. Tom spent ten years as a sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.
|
| Mr Mark Davies | Non-Executive DirectorNon-Executive Chairman | Apr 2019 |
Mr Davies has over 20 years of experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital. Mark specializes in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
|
| Mr Gerald Quigley | Non-Executive DirectorDirector of Public Relations | Jul 2022 |
Mr Quigley is a Pharmacist and consumer health commentator. As a media health commentator heard each week on television and radio stations across Australia. He has knowledge relating to pharmaceutical and nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (e.g. TGA, FDA)
|
| Mrs Erlyn Dawson | Company Secretary | Apr 2019 |
-
|
| Ms Alessandra Gauvin | Joint Company Secretary | Mar 2024 |
-
|
| Alexandra Andrews | Chief Operation Officer |
-
|
|
| Erlyn Dawson | Company Secretary |
-
|
|
| Alessandra Gauvin | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J & J Bandy Nominees Pty Ltd <Bandy P/F A/C> | 41,796,178 | 4.11% |
| Jalaver Pty Ltd <Falcon Pension A/C> | 40,268,347 | 3.96% |
| Dutch Ink (2010) Pty Ltd | 37,000,000 | 3.64% |
| Dutch Ink (2010) Pty Ltd i | 33,897,522 | 3.33% |
| The Trust Company (Australia) Limited <MOF A/C> | 30,506,500 | 3.00% |
| Chincherinchee Nominees Pty Ltd | 27,693,572 | 2.72% |
| The Trust Company (Australia) Limited <MBF A/C> | 26,850,255 | 2.64% |
| Gleneagle Securities Nominees Pty Limited | 26,829,185 | 2.64% |
| Citicorp Nominees Pty Limited | 26,781,993 | 2.63% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 25,013,360 | 2.46% |
| Mrs Melanie Therese Verheggen | 18,017,328 | 1.77% |
| MB Investment Capital Pty Ltd | 17,084,226 | 1.68% |
| Gofour Sail Pty Ltd | 17,073,000 | 1.68% |
| Quadrangle Capital Pty Ltd | 14,000,000 | 1.38% |
| Mr Vedat Isikgel | 12,649,999 | 1.24% |
| Mr Patrick Pasquale Steve Calabria <Dolce Elite A/C> | 12,000,000 | 1.18% |
| Buttonwood Nominees Pty Ltd | 11,525,396 | 1.13% |
| Max Cap Investments Pty Ltd | 11,080,000 | 1.09% |
| The Sun W Investment Pty Ltd <Sun Family A/C> | 11,027,272 | 1.08% |
| J & J Bandy Nominees Pty Ltd <J & J Bandy Super Fund A/C> | 9,500,000 | 0.93% |
